downloaded from on june 10, 2020 by guest · 07/09/2011 · 46 (9, 11). consequently, it is...
TRANSCRIPT
1
Title: Development of a multiplexed and automated serotyping assay for Streptococcus 1
pneumoniae 2
3
Running Title: Automated and complete pneumococcal serotyping assay 4
5
Jigui Yu1, Jisheng Lin1, Kyung-Hyo Kim2, William H. Benjamin, Jr. 1, and Moon H. Nahm1* 6
7
1 Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, 2 8
Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Korea. 9
10
Corresponding Author: Moon H. Nahm, MD 11
Department of Pathology 12
University of Alabama at Birmingham 13
BBRB 614 14
1530 Third Avenue South 15
Birmingham, AL 35294-2170 16
Tel: 205-934-0163 17
Fax: 205-975-2149 18
20
21
22
Copyright © 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.Clin. Vaccine Immunol. doi:10.1128/CVI.05312-11 CVI Accepts, published online ahead of print on 7 September 2011
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
2
Abstract 23
Streptococcus pneumoniae expresses more than 90 capsule types and currently available 24
pneumococcal vaccines are designed to provide serotype specific protection. Consequently, 25
serotyping pneumococcal isolates is important to determine serotypes to be included in 26
pneumococcal vaccines and to monitor their efficacy. Yet, serotyping pneumococcal isolates 27
has remained a significant technical challenge. By multiplexing many assays, we have now 28
developed a simple yet comprehensive serotyping assay system that can not only identify all 29
known pneumococcal serotypes but also subdivide non-typeable (NT) isolates into those with or 30
without the conventional capsule locus. We have developed this assay system to require only 31
six key reagents: two are used in one multiplex inhibition-type immunoassay and four are 32
required in two multiplex PCR-based assays. The assay system is largely automated by a 33
seamless combination of monoclonal antibody-based and PCR-based multiplex assays using 34
the flow-cytometric bead array technology from Luminex®. The assay system has been 35
validated with a panel of pneumococci expressing all known pneumococcal serotypes and was 36
found to be easily transferable to another laboratory. 37
38
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
3
Introduction 39
Streptococcus pneumoniae is an important human pathogen expressing more than 90 40
serologically distinct polysaccharide (PS) capsules (5, 12, 21). Currently available 41
pneumococcal vaccines provide serotype-specific protection (1, 23). Consequently, in the wake 42
of unqualified success of the 7-valent conjugate vaccine, serotypes covered by the vaccine 43
have become uncommon whereas non-vaccine serotypes have become more common than 44
before (13, 28). Also pneumococcal serotype prevalence differs for different locations and time 45
(9, 11). Consequently, it is important to survey serotypes of pneumococcal isolates circulating 46
in many populations to monitor efficacy of current vaccines and to select serotypes for future 47
vaccines. 48
49
Classically, pneumococci are serotyped by the quellung reaction (12, 17). However, technically 50
the quellung reaction is very labor intensive and several new approaches have appeared. One 51
approach utilizes PCR-based systems that analyze DNA sequences of the capsular 52
polysaccharide synthesis gene locus (cps) which contains the genes for capsule biosynthesis 53
(3, 4, 15, 16, 19, 24). Another approach is a multiplex immunoassay for capsular 54
polysaccharides (PS) using a set of monoclonal antibodies (mAbs) to identify the vaccine 55
related serotypes (30). While these two approaches overcome some of the limitations 56
associated with the quellung reaction, they still have significant limitations. For instance, 57
identification of PCR products commonly used manual electrophoresis (20) or line-blot 58
hybridization (15). Also, due to vaccine-caused shifts in serotype prevalence, the multiplex 59
immunoassay with limited coverage can no longer identify the serotype of a large fraction of 60
contemporary isolates. Consequently, pneumococcal serotyping still remains a challenge to 61
most laboratories. 62
63
An ideal serotyping system should not only be simple to perform but should also cover all 64
pneumococcal serotypes. The ability to test for all known serotypes is important because the 65
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
4
serotype prevalence not only varies due to vaccine-induced serotype shifts but also varies 66
among different regions (11) or over time (9). Also, the vaccine usage may increase the 67
prevalence of non-typeable (NT) pneumococci (25), which in turn are heterogeneous. A study 68
(10) divided them into two groups: Group I isolates have conventional but defective cps but 69
Group II has non-conventional cps with novel genes (10). Clade 1 isolates of Group II NT 70
isolates have pspK (pneumococcal surface protein K), clade 2 has ali-B like ORF1 (herein 71
named aliC for simplicity) and ali-B like ORF2 (named aliD), and clade 3 has aliC [(10), Park et 72
al. unpublished data]. To develop a simple yet comprehensive pneumococcal serotyping 73
system, we have seamlessly combined the PCR and mAb based approaches and produced an 74
automated and multiplexed typing system that is simple to perform, and can be easily 75
transferred to another laboratory. 76
77
Methods 78
1) Bacterial strains 79
Our study used a panel of bacteria that was comprised of 290 isolates. The panel included 90 80
isolates purchased from the Statens Serum Institute (Copenhagen, Denmark) representing the 81
90 different pneumococcal serotypes previously described (12). In addition, pneumococci 82
expressing the three newly described serotypes (6C, 6D, and 11E), a laboratory strain with no 83
capsule (R36A), and three clades of NT clinical isolates with null capsule genes, recently 84
described by us (Park et al. unpublished data), were also included. The panel had five clinical 85
isolates for each serotype 1, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 11E, 12F, 14, 15B, 86
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, four isolates expressing serotype 2, and three 6D 87
isolates. The panel included 53 clinical isolates of pneumococci expressing the serotypes not 88
included in the 23-valent PS vaccine and NT pneumococci that were obtained from the Centers 89
for Disease Control and Prevention (CDC) (Table 4). In addition to pneumococci, the panel also 90
contained isolates from several closely related species: one isolate of Streptococcus mutans, 91
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
5
three isolates of Streptococcus mitis and three isolates of Streptococcus oralis. It also had one 92
isolate each from S. pyogenes and S. agalactiae. 93
94
All bacterial isolates were recovered from frozen vials on blood agar plates and isolated 95
colonies were cultured in THY medium overnight. The pneumococci in the liquid cultures were 96
lysed as described (30) and the lysates were stored at -20°C until needed. These lysates were 97
used for our serotyping system with 3 reactions: Reaction A consists of 26 PSs detected with 98
mAbs and Reactions B and C are PCR based as described below. 99
100
2) Coupling polysaccharides to microspheres 101
Each of 26 pneumococcal capsular PSs (serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 102
11A, 11E, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) were conjugated to one of 103
26 types of Microplex microspheres (Luminex, San Antonio, TX). All of the PSs were purchased 104
from ATCC (Manassas, VA) except 6A, 6C and 11E. 6A PS was obtained from Dr. G. 105
Schiffman (Brooklyn, NY), but 6C and 11E PSs were purified in our laboratory (21, 32). For 106
each of the PS, twelve million carboxyl MicroPlex microspheres (Luminex, San Antonio, TX) 107
were washed twice in MES buffer (100 mM MES in water, pH=6) and re-suspended in 1 ml of 108
ADH (Adipic acid dihydrazide) solution (35 mg/ml of ADH in MES buffer) and mixed with 200 μl 109
of EDC (1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride) solution (200 mg/ml of 110
EDC in MES Buffer). The reaction mixture was briefly sonicated using a Bransonic 2200 111
sonicator (Danbury, CT) and vortexed gently before being incubated for 1 hour at RT in the 112
dark. The beads were washed with water and re-suspended in 400 μl of water. The re-113
suspended beads were mixed with 320 μl of a PS solution and 80 μl of EDC solution (100 114
mg/ml of EDC in water), then incubated with shaking at 37o C for various periods. PS 115
concentrations (10-250 μg/ml) and incubation periods (1 to 18 hours) varied for different 116
serotypes. After the incubation, 80 μl of 500 mM glucose and 80 μl of 500 mM of glycine (pH=7) 117
were added to the reaction mixture. After a 30 minute incubation at RT with shaking, the beads 118
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
6
were washed with the Wash Buffer (PBS with 0.1% tween-20 and 0.02% sodium azide) and re-119
suspended in 1 ml of Storage Buffer (PBS with 0.01% Tween-20, 1% BSA, 0.1% glucose, and 120
0.02% sodium azide). After aging the bead for 10 days at 4oC, the Stock Bead Mixture was 121
made by mixing all 26 bead suspensions together with 54 ml of storage buffer, and it was stored 122
frozen in 1 ml aliquots. 123
124
3) Multibead serotyping assay with mAb (Reaction A) 125
One frozen vial of PS-coated Stock Bead Mixture was thawed, diluted 3-fold with 2 mL of 126
Blocking Buffer (PBS with 0.1% Tween-20, 0.02% sodium azide, and 1% BSA) and 127
resuspended by sonicating. Twenty-five μl of the bead mixture was added to each well of a 96-128
well plate with a filter bottom (Thermo Fisher, Waltham, MA) and the beads were washed twice 129
with Wash Buffer using vacuum-suctioning. After resuspending the beads with 25 μl of Blocking 130
Buffer, 25 μl of one diluted bacterial lysate and 25 μl of the diluted mAb pool were added to 131
each well. The diluted bacterial lysates were prepared by diluting the bacterial lysates 10 or 30 132
fold in Blocking Buffer. The mAb Pool was prepared by mixing 26 different hybridoma culture 133
supernatants (Table 1), stored frozen in 1 mL aliquots, and then diluted 3-fold with Blocking 134
Buffer before use. After a 30 minute incubation at RT in the dark with shaking (700 rpm), the 135
plate was washed four times with the Wash Buffer. To detect bound mAb, 50 μl of PE-136
conjugated goat anti-mouse immunoglobulin (BD Pharmingen, Franklin Lakes, NJ) was diluted 137
1:200 in Blocking Buffer and added to each well. The plates were incubated for 30 minutes in 138
the dark with shaking. After washing 4 times, the beads were re-suspended in 75 μl of Wash 139
Buffer and the 96 well plate was then incubated for 2 hours in the dark at RT before being 140
placed in a Bio-Plex 200 Analyzer (Biorad, Hercules, CA) to acquire the fluorescence data. The 141
fluorescence data of each sample for each serotype were converted to normalized signal as 142
following: [Normalized signal=100*(sample signal-background signal)/(blank control signal-143
background signal) ] For an unknown sample, the serotype with normalized signal less than 144
33% was selected as its serotype. To facilitate data analysis, a computer program generated a 145
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
7
table containing normalized signals of all serotypes for each sample. The normalized signals 146
were in red color when the signals were less than 33%, were in blue color when they were 147
between 33 and 67%, and were in black when they were above 67%. 148
149
4) Coupling DNA probes to microspheres 150
To prepare beads for conjugation, 2 million carboxyl MicroPlex microspheres (Luminex, San 151
Antonio, TX) were washed with water before being suspended in 50 μL of 0.1 M MES, pH 4.5 by 152
sonication. Two μL of the oligonucleotide probe stock (100 μM in water, kept at -20°C) and 2.5 153
μL of fresh EDC solution (10 mg/ml in MES) was added to the bead suspension and the 154
reaction mixture was mixed well and incubated for 30 minutes at RT in the dark with shaking. 155
After the first incubation, 2.5 μL of fresh EDC solution (10 mg/mL) was added to the reaction 156
mixture before another 30 minute incubation at RT in the dark with shaking. The beads were 157
washed with 1 mL of 0.02% Tween-20, then with 1 mL of 0.1% SDS, and were re-suspended in 158
400 μL of TE buffer (10 mM Tris-1mM EDTA, pH 8.0) by vortexing and sonication. All of the 159
beads were mixed together and the resulting bead pool (Stock Bead Mixture) was stored frozen 160
in 0.4 ml aliquots. 161
162
5) Multibead serotyping assay with multiplex PCR (Reactions B and C) 163
For serotypes not identified with mAbs, two multiplex PCR reactions were performed in 25 μl 164
volumes containing 5 μl of bacterial lysate (diluted 1:50) and 20 μl of PCR reaction mixture. The 165
PCR reaction mixture was made by mixing 990 μl of 2X Primer Pool, 990 μl of water, and 20 μl 166
(100 U) of Ex-Taq DNA polymerase (Takara ExTag polymerase, Madison, WI). One aliquot 167
(990 μl) of 2X Primer Pool is made by mixing 250 μl of 10X Ex-taq buffer (Takara, Madison, WI), 168
200 μl of 2.5 mM dNTP, and 6.25 μl of each stock primer (except lytA) in Table 2, followed by 169
adding enough water to make the final volume 990 μl. Instead of 6.25 μl, only 5.0 μl of lytA 170
primer stocks were added. One of each primer pair has a biotin label at the 5’ end for detection 171
with streptavidin. Thermal cycling was performed in Eppendorf Mastercycler gradient system 172
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
8
(Eppendorf, Westbury, New York) using the following conditions: 94°C for 15 minutes followed 173
by 35 amplification cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute, 174
then 72oC for 10 minutes for extension. The PCR products were kept at 4°C until further 175
analysis. 176
177
To identify the PCR amplicons, 20 μl of 1:100 diluted PCR reaction mixture was transferred to a 178
96-well PCR plate and heated for 10 minutes at 95oC. One aliquot of DNA-coupled Stock Bead 179
Mixture corresponding to the PCR reaction was thawed and washed with 1XTMAC buffer (3 M 180
TMAC, 1 g/L SDS, 50 mM Tris-HCl, 4 mM EDTA, pH 8.0) by centrifugation. The beads were 181
then suspended in 4 mL of 1.5XTMAC at 48°C and briefly sonicated. 40 μl of the bead mixture 182
was quickly transferred to each well and mixed with the PCR product by brief vortexing. The 183
plate was incubated at 48°C for 30 minutes in the dark. 135 μl of 1XTMAC (48oC) was added to 184
each well of the PCR plate and mixed before the entire content in each well was transferred to a 185
filter plate (Millipore, Billerica, MA). After washing the plate with 1XTMAC, 50 μl of PE-186
Streptavidin (BD Pharmingen in Franklin Lakes, NJ) was added to each well of the plate. After 187
a 20 minute incubation at 48°C, the plate was washed once with 1XTMAC and then with PBS-188
0.1% Tween-20 once. The beads were re-suspended in 75 μl of PBS-0.1% Tween-20 and the 189
filter plate was inserted into a Bio-Plex 200 Analyzer (Biorad, Hercules, CA) to acquire the 190
fluorescence data. Fluorescence signal was converted to the signal to noise (S/N) ratio by 191
dividing fluorescence signals of sample by the background signals for each serotype. All the 192
control samples produced S/N ratio less than 4 for incorrect serotypes and greater than 30 for 193
the correct serotypes. For an unknown sample, the serotype with S/N ratio greater than 10 was 194
chosen as its serotype. To facilitate data analysis, a computer program generated a table 195
containing S/N ratios of all serotypes for each sample. The S/N ratios were in red color when 196
S/N ratios were greater than 10, were in blue color when they were between 3 and 10, and were 197
in black when they were below 3. 198
199
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
9
Results 200
1) Characterization of mAb-based multibead serotyping assays (Reaction A) 201
Although we have previously described a multiplexed immunoassay for 26 vaccine related 202
serotypes using mAbs (30), it had a low degree of multiplexing and required several separate 203
assays. We have now overcome these limitations by developing a 26-fold multiplexed assay 204
with a new set of 26 different mAbs (Table 1). While 16 mAbs were mono-specific, 10 mAbs 205
were multi-specific as they reacted with related serotypes (Table 1). Multi-specificity of cross-206
reactive mAbs would not cause difficulties in serotype surveillance however since the cross-207
reactive serotypes such as 7A or 9A are rare and are epidemiologically insignificant. 208
209
In the assay configuration used here, the multi-specific antibodies were fully cross-reactive as 210
illustrated with a 9A/9V-specific antibody (Figure 1B) except for the two mAbs (Hyp11AM1 and 211
Hyp15BG5). Hyp11AM1 preferentially bound to 11E serotype and weakly reacted with 11A, 212
11D, and 11F serotypes. Since Hyp11AM1 is used to identify 11E isolates only and another 213
mAb (Hyp11AM2) is used to identify 11A, 11D, and 11F serotypes, the unequal binding pattern 214
of Hyp11AM1 caused no difficulties. In the case of serotypes 15B/15C, Hyp15BG5 reacted with 215
15C less efficiently, but the unequal cross-reactivity is not relevant as serotypes 15B and 15C 216
interconvert in vitro (26, 27). 217
218
The specificity of the tests included in this mAb-based multiplex assay, which is named 219
Reaction A, was then examined with a panel of pneumococcal isolates representing all 93 220
known pneumococcal serotypes as well as both Groups of NT pneumococci and some non-221
pneumococcal streptococcal species (Figures 1A and 1B). Non-pneumococcal isolates 222
produced normalized (fluorescence) signals more than 67%. All pneumococcal isolates 223
produced normalized signal less than 33% for the tests of their own or cross-reactive serotypes 224
but more than 67% for other unrelated serotypes. Figure 1 shows normalized signals for two 225
tests (serotypes 14 and 9V) obtained with all the isolates in the test panel and Table 1 shows 226
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
10
the summary of the specificity for all the tests. Normalized signal of 33% was used as the cut 227
off for unknown samples. Sensitivities of the tests included in Reaction A were determined 228
using purified capsular PS. Although the sensitivities varied by more than 100 fold among the 229
tests, all the tests in Reaction A showed significant inhibition (i.e., <50% of normalized signal) at 230
80 ng/ml of capsular PS (Figure 2, Table 1) and the concentrations of the PS inhibiting 50% of 231
the mAb binding (IC50) are shown in Table 1. These sensitivities were sufficient to identify 232
serotypes even when a pneumococcal lysate was diluted 100 fold (data not shown). 233
234
2) Characterization of the PCR-based multibead serotyping assays (Reactions B and C) 235
Although there are multiplexed PCR methods for typing pneumococci in the literature (15, 20, 236
33), generally cumbersome methods are used to identify PCR products (15, 20) and the degree 237
of multiplexing is low (20). We used high degrees (21 and 22 fold) of multiplexing and simplified 238
the identification of PCR products by using Luminex® technology. Two PCR-based assays, 239
which are named Reactions B and C, include tests for the serotypes that were not covered by 240
the Reaction A except for tests for 6C/6D and 15B/15C. Tests for 6C/6D are in both Reactions 241
A and B since 6C/6D test was developed for Reaction B before a suitable mAb was developed 242
for Reaction A. The test for 15B/15C was included to independently monitor performance of the 243
15B-specific mAb that is unequally cross-reactive for 15C. 244
245
In addition to serotype-specific tests, tests for lytA and cpsA were added to Reactions B and C 246
to confirm the species identification as pneumococci (Table 2, 3). Two cpsA tests were included 247
because the first cpsA test does not detect cpsA of serotypes 25A, 25F, and 38 (20) but the 248
second cpsA test does. Reaction C has tests for genes such as aliC, aliD, and pspK to classify 249
Group II NT pneumococci which are cpsA-. In contrast, Group I NT pneumococci are cpsA+ 250
(10). Even with these additional and overlapping tests, all 43 target genes could be detected 251
easily and quickly with only two PCR reactions and the Luminex® detection assays. 252
253
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
11
The specificity of Reactions B and C was examined with a panel of pneumococci including all 93 254
pneumococcal serotypes and both Groups of NT pneumococci (Figures 1C and 1D). All 255
pneumococcal isolates produced S/N ratio greater than 30 for the tests of their own serotypes 256
but less than 4 for other serotypes. Non-pneumococcal isolates produced S/N ratio less than 2. 257
Figure 1 shows examples of a mono-specific test (serotype 21) and a multi-specific test 258
(serotypes 33F, 33A, and 37) results obtained with the bacterial isolates in the test panel. S/N 259
ratio of 10 was chosen as the cut off for unknown samples and specificities of all assays are 260
summarized in Table 2. The assay is sensitive enough to detect 5 pg of DNA, which 261
corresponds to ~2000 copies of pneumococcal DNA. In practical terms, most of the lysates 262
could be diluted an additional 50-fold and therefore the assay has sufficient sensitivity for 263
practical uses. 264
265
3) Analysis of archived clinical isolates with mAb and PCR tests 266
Although all the tests in our assay system were tested with a test panel including all known 267
serotypes, Reaction A was reevaluated with a panel of clinical isolates which included three 6D 268
isolates, four serotype 2 isolates and five isolates each of the serotypes 1, 3, 4, 5, 6A, 6B, 6C, 269
7F, 8, 9N, 9V, 10A, 11A, 11E, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. All 270
clinical isolates were correctly identified (Supplementary Table 1). 271
272
Testing Reactions B and C with clinical isolates was difficult because the serotypes detected by 273
the two Reactions are not common. Nevertheless, we tested our assay with 53 clinical isolates 274
expressing the serotypes relevant to Reactions B and C. Concordant results were obtained with 275
all isolates (Table 4). Three samples that were originally identified to be NT were cpsA+, pspK-, 276
aliC- and aliD-. The 3 isolates therefore belong to Group I NT with defective cps loci (10). 277
278
4) Testing mixtures of two different serotypes. 279
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
12
Although our assay was designed for individual isolates of pneumococci, our assay is inherently 280
capable of detecting multiple serotypes in one sample. To investigate this capability, we 281
prepared three pneumococcal lysates spiked with a secondary serotype at 1% or 10% level. 282
One was a type 3 lysate spiked with serotype 6B, another was a type 5 lysate with type 12F, 283
and third was type 19F mixed with 33F. Serotypes used for spiking were chosen because the 284
test was least sensitive (serotype 6B) or lysates had low titer, and therefore these spiked 285
samples provided stringent testing conditions. When the samples were tested with Reaction A, 286
the primary serotype was identified without difficulty in all samples. The secondary serotypes 287
could be easily identified (<33%) in all 3 samples containing 10% (Figure 3) but the samples 288
containing the secondary serotype at 1% produced normalized signals that were substantially 289
reduced (<67%) but not below 33%. Although additional studies are needed, Reaction A should 290
identify all secondary serotypes present in 10% abundance level but may not identify some 291
secondary serotypes in 1% abundance level. Analogous studies of Reactions B and C suggest 292
that they should detect the secondary serotypes present at 0.1~1% abundance. 293
294
5) Portability of the assay system 295
We found that the six key reagents (1 mAb Pool, 2 Primer Pools, and 3 Bead Mixtures) have 296
long shelf lives. To investigate if our system is simple and robust enough to be transferred to 297
another laboratory with minimal experience in serotyping, we sent the six key reagents, our 298
assay protocol, and 75 test samples to Dr. K. H. Kim’s laboratory in Seoul, Korea equipped with 299
equivalent equipment (Bio-Plex). The test samples were blinded and included 72 samples 300
representing all 69 serotyping reactions performed by the assay system. Seven samples were 301
mixtures of two serotypes. The laboratory was able to establish all three reactions with ease 302
and correctly identified all of the samples. 303
304
Discussion 305
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
13
Since currently available pneumococcal vaccines provide serotype specific protection and alter 306
the distribution of pneumococcal serotypes, continued surveillance of serotypes of 307
pneumococcal isolates is critical in monitoring pneumococcal vaccine efficacy and in improving 308
vaccine formulations. However, the classical typing method used by many laboratories is labor 309
intensive and therefore serotyping surveillance is often limited to a small number of isolates and 310
to a few commonly found serotypes. By modifying and combining various approaches 311
developed by us and others (8, 15, 20, 30), we have now developed a simple yet 312
comprehensive serotyping assay system that can test pneumococcal isolates for all the known 313
serotypes with only three multiplexed assays performing 69 different tests with only 6 key 314
reagents (1 mAb Pool, 2 Primer Pools, and 3 Bead Mixtures). The assay system is rapid and 315
largely automated due to the use of flow cytometric bead array technology (or Luminex® 316
method). Although the assay uses microtiter plates to accommodate many isolates, it can be 317
used with individual tubes (e.g., Eppendorf tubes) for handling a few samples. In addition, the 318
assay system is robust enough to be transferred to a distant laboratory with a suitable 319
instrument but little experience in serotyping pneumococci. In summary, our assay system has 320
overcome current limitations in serotyping pneumococci and should vastly simplify 321
pneumococcal serotype surveillance. 322
323
Our assay system differs from other assays in several ways. First, although there are 324
automated assay systems using Luminex® technology similar to ours, unlike our system, these 325
systems can detect only a limited (e.g., 40) number of serotypes that are common 326
(http://www.luminexcorp.com/Products/Instruments/MAGPIX/MAGPIX-SEPTEMBER-WINNER, 327
accessed June 28, 2011). Second, our system is highly flexible due to seamless integration of 328
immunoassays and DNA assays that share the sample types and the assay platform. 329
Consequently, our system can be readily expanded by adding either an immuno- or DNA 330
assays, which have complementary strengths and weaknesses (8, 18). The expandability 331
allowed us to add several additional tests for identifying S. pneumoniae species in Reaction B 332
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
14
and C. Lastly, our assay system is easy to standardize because it uses well defined and 333
extensively characterized reagents such as oligonucleotides and mAbs. 334
335
Despite strengths, our assay system does have some limitations. Our system does not 336
distinguish some serotypes (e.g., 9A and 9V, serotypes 33A, 33F, and 37) and resolution of 337
such serotyping ambiguities would require conventional manual methods based on polyclonal 338
factor sera or specific DNA tests. Although we anticipate that these serotyping ambiguities 339
should not cause practical difficulties in serotype surveillance, if necessary, additional tests may 340
be incorporated into our assay system. Another limitation may be that our system has been 341
developed for testing individual isolates of pneumococcus. This restriction may be undesirable 342
in studies of nasopharyngeal carriage of pneumococci because the nasopharyx frequently 343
harbors multiple serotypes (2) and identifying all the serotypes in the nasopharynx would require 344
testing many isolates from a single swab. The restriction was imposed by us because 345
pneumococcal and non-pneumococcal cps can be very similar to each other (29) and non-346
pneumococci may be the source of the targets being detected by any DNA detection system. 347
Such false positive detection may also occur with mAb-based immunoassays. However our 348
assay system is intrinsically capable of detecting multiple serotypes in a sample and the genetic 349
similarity may not cause practical problems. Consequently, the restriction of using isolates 350
should be re-evaluated in the future by studying nasopharyngeal swabs or their broth 351
enrichments (7) along with pneumococcal isolates from the swabs. 352
353
The vaccine related serotypes that were included in Reaction A could have been tested with 354
PCR as we have done for other serotypes. Nevertheless, the use of mAbs for Reaction A 355
provides several advantages. First, serotype surveillance often requires testing pneumococcal 356
isolates only for the vaccine-related serotypes and the mAb-based Reaction A would satisfy this 357
need simply, without PCR. Also the immunoassay provides more reliable serotyping 358
information since it directly tests capsule structure unlike DNA tests, which provide indirect 359
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
15
information. This was illustrated with a 19F strain that was genetically more similar to 19A (22) 360
and with serotype 11A isolates that could not be genetically distinguished from serotype 11D 361
(6). Also its ability to quantitatively measure capsular PS in samples can be valuable. For 362
instance, with the immunoassay, pleural fluids were found to contain enough capsular PS to 363
neutralize anti-PS antibodies present in the host (31). Reaction A should be useful in vaccine 364
production as well since it can be used to quantify capsular PS during its purification and 365
conjugation. 366
367
Because of difficulties of typing pneumococci, our knowledge of pneumococcal serotype 368
prevalence is limited to select geographical areas and deficient in a large part of the world. The 369
areas with limited studies may have different serotype distribution or harbor unusual serotypes. 370
As our assay can identify all serotypes and be placed in laboratories with little experience in 371
serotyping, the system should facilitate surveys of pneumococcal serotypes in different parts of 372
the world. Since our assay can serotype pneumococcal isolates completely including different 373
clades of Group II NT pneumococci, we may find new capsule types. Perhaps our assay 374
system may help us discover new serotypes and new clades among NT pneumococci as well 375
as complete surveillance in different parts of the world. 376
377
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
16
Acknowledgments 378
We thank Dr. C. Steele for allowing us to use his Bio-Plex® instrument, Dr. B. Beall at CDC for 379
generous support with bacterial isolates, and Dr. K. Honjo for tireless technical assistance. 380
381
The work was supported by NIAID-DMID-AI-30021 to MHN. The University of Alabama at 382
Birmingham has IP rights on monoclonal antibodies and has applied for a patent on 6C and 6D 383
serotypes. MHN, JY, JL, and WHB are employees of the university. 384
385
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
17
References 386
387
1. 2010. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and 388
recommendations for use among children - Advisory Committee on Immunization 389
Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 59:258-261. 390
2. Austrian, R. (ed.). 2000. The enduring pneumococcus: Unfinished business and 391
opportunities for the future. Mary Ann Liebert, Inc, Larchmont, NY. 392
3. Batt, S. L., B. M. Charalambous, T. D. McHugh, S. Martin, and S. H. Gillespie. 2005. 393
Novel PCR-restriction fragment length polymorphism method for determining serotypes 394
or serogroups of Streptococcus pneumoniae isolates. J. Clin. Microbiol. 43:2656-2661. 395
4. Brito, D. A., M. Ramirez, and H. de Lencastre. 2003. Serotyping Streptococcus 396
pneumoniae by multiplex PCR. J. Clin. Microbiol. 41:2378-2384. 397
5. Calix, J. J., and M. H. Nahm. 2010. A new pneumococcal serotype, 11E, has variably 398
inactivated wcjE gene. J Infect Dis 202:29-38. 399
6. Camilli, R., R. J. Bonnal, M. Del Grosso, M. Iacono, G. Corti, E. Rizzi, M. Marchetti, 400
L. Mulas, F. Iannelli, F. Superti, M. R. Oggioni, G. De Bellis, and A. Pantosti. 2011. 401
Complete genome sequence of a serotype 11A, ST62 Streptococcus pneumoniae 402
invasive isolate. BMC Microbiol 11:25. 403
7. da Gloria Carvalho, M., F. C. Pimenta, D. Jackson, A. Roundtree, Y. Ahmad, E. V. 404
Millar, K. L. O'Brien, C. G. Whitney, A. L. Cohen, and B. W. Beall. 2010. Revisiting 405
pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced 406
detection of carriage and serotypes. J Clin Microbiol 48:1611-1618. 407
8. Dunbar, S. A., C. A. Vander Zee, K. G. Oliver, K. L. Karem, and J. W. Jacobson. 408
2003. Quantitative, multiplexed detection of bacterial pathogens: DNA and protein 409
applications of the Luminex LabMAP system. J Microbiol Methods 53:245-252. 410
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
18
9. Finland, M., and M. W. Barnes. 1977. Changes in occurrence of capsular serotypes of 411
Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 412
and 1974. J Clin Microbiol 5:154-166. 413
10. Hathaway, L. J., P. Stutzmann Meier, P. Battig, S. Aebi, and K. Muhlemann. 2004. A 414
homologue of aliB is found in the capsule region of nonencapsulated Streptococcus 415
pneumoniae. J Bacteriol 186:3721-3729. 416
11. Hausdorff, W. P., G. Siber, and P. R. Paradiso. 2001. Geographical differences in 417
invasive pneumococcal disease rates and serotype frequency in young children. Lancet 418
357:950-952. 419
12. Henrichsen, J. 1995. Six newly recognized types of Streptococcus pneumoniae. J. Clin. 420
Microbiol. 33:2759-2762. 421
13. Hicks, L. A., L. H. Harrison, B. Flannery, J. L. Hadler, W. Schaffner, A. S. Craig, D. 422
Jackson, A. Thomas, B. Beall, R. Lynfield, A. Reingold, M. M. Farley, and C. G. 423
Whitney. 2007. Incidence of pneumococcal disease due to non-pneumococcal 424
conjugate vaccine (PCV7) serotypes in the United States during the era of widespread 425
PCV7 vaccination, 1998-2004. J Infect Dis 196:1346-1354. 426
14. Kong, F., M. Brown, A. Sabananthan, X. Zeng, and G. L. Gilbert. 2006. Multiplex 427
PCR-based reverse line blot hybridization assay to identify 23 Streptococcus 428
pneumoniae polysaccharide vaccine serotypes. J Clin Microbiol 44:1887-1891. 429
15. Kong, F., W. Wang, J. Tao, L. Wang, Q. Wang, A. Sabananthan, and G. L. Gilbert. 430
2005. A molecular-capsular-type prediction system for 90 Streptococcus pneumoniae 431
serotypes using partial cpsA-cpsB sequencing and wzy- or wzx-specific PCR. J. Med. 432
Microbiol. 54:351-356. 433
16. Lawrence, E. R., D. B. Griffiths, S. A. Martin, R. C. George, and L. M. Hall. 2003. 434
Evaluation of semiautomated multiplex PCR assay for determination of Streptococcus 435
pneumoniae serotypes and serogroups. J. Clin. Microbiol. 41:601-607. 436
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
19
17. Lund, E. 1960. Laboratory diagnosis of Pneumococcus infections. Bull.Wld. Hlth. Org. 437
23:5-13. 438
18. Miller, M. B., and Y. W. Tang. 2009. Basic concepts of microarrays and potential 439
applications in clinical microbiology. Clin Microbiol Rev 22:611-633. 440
19. O'Halloran, D. M., and M. T. Cafferkey. 2005. Multiplex PCR for identification of seven 441
Streptococcus pneumoniae serotypes targeted by a 7-valent conjugate vaccine. J. Clin. 442
Microbiol. 43:3487-3490. 443
20. Pai, R., R. E. Gertz, and B. Beall. 2006. Sequential multiplex PCR approach for 444
determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 445
44:124-131. 446
21. Park, I. H., D. G. Pritchard, R. Cartee, A. Brandao, M. C. Brandileone, and M. H. 447
Nahm. 2007. Discovery of a new capsular serotype (6C) within serogroup 6 of 448
Streptococcus pneumoniae. J. Clin. Microbiol. 45:1225-1233. 449
22. Pimenta, F. C., R. E. Gertz, Jr., A. Roundtree, J. Yu, M. H. Nahm, R. R. McDonald, 450
G. Carvalho Mda, and B. W. Beall. 2009. Rarely occurring 19A-like cps locus from a 451
serotype 19F pneumococcal isolate indicates continued need of serology-based quality 452
control for PCR-based serotype determinations. J Clin Microbiol 47:2353-2354. 453
23. Robbins, J. B., R. Austrian, C. J. Lee, S. C. Rastogi, G. Schiffman, J. Henrichsen, 454
P. H. Makela, C. V. Broome, R. R. Facklam, R. H. Tiesjema, and J. C. Parke, Jr. 455
1983. Considerations for formulating the second-generation pneumococcal capsular 456
polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect 457
Dis 148:1136-1159. 458
24. Rubin, L. G., and A. Rizvi. 2004. PCR-based assays for detection of Streptococcus 459
pneumoniae serotypes 3, 14, 19F and 23F in respiratory specimens. J. Med. Microbiol. 460
53:595-602. 461
25. Sa-Leao, R., S. Nunes, A. Brito-Avo, N. Frazao, A. S. Simoes, M. I. Crisostomo, A. 462
C. Paulo, J. Saldanha, I. Santos-Sanches, and H. de Lencastre. 2009. Changes in 463
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
20
pneumococcal serotypes and antibiotypes carried by vaccinated and unvaccinated day-464
care centre attendees in Portugal, a country with widespread use of the seven-valent 465
pneumococcal conjugate vaccine. Clin Microbiol Infect 15:1002-1007. 466
26. van Selm, S., L. M. van Cann, M. A. Kolkman, B. A. van der Zeijst, and J. P. van 467
Putten. 2003. Genetic basis for the structural difference between Streptococcus 468
pneumoniae serotype 15B and 15C capsular polysaccharides. Infect. Immun. 71:6192-469
6198. 470
27. Venkateswaran, P. S., N. Stanton, and R. Austrian. 1983. Type variation of strains of 471
Streptococcus pneumoniae in capsular serogroup 15. J. Infect. Dis. 147:1041-1054. 472
28. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. 473
Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, 474
and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the 475
introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-476
1746. 477
29. Yang, J., M. Ritchey, Y. Yoshida, C. A. Bush, and J. O. Cisar. 2009. Comparative 478
structural and molecular characterization of ribitol-5-phosphate-containing Streptococcus 479
oralis coaggregation receptor polysaccharides. J Bacteriol 191:1891-1900. 480
30. Yu, J., G. Carvalho Mda, B. Beall, and M. H. Nahm. 2008. A rapid pneumococcal 481
serotyping system based on monoclonal antibodies and PCR. J Med Microbiol 57:171-482
178. 483
31. Yu, J., D. Salamon, M. Marcon, and M. H. Nahm. 2011. Pneumococcal serotypes 484
causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol 49:534-485
538. 486
32. Zartler, E. R., R. J. Porambo, C. L. Anderson, L. H. Chen, J. Yu, and M. H. Nahm. 487
2009. Structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a 488
novel acetylglycerol that is the structural basis for 11A subtypes. J Biol Chem 284:7318-489
7329. 490
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
21
33. Zhou, F., F. Kong, Z. Tong, and G. L. Gilbert. 2007. Identification of Less-Common 491
Streptococcus pneumoniae Serotypes by a Multiplex PCR-Based Reverse Line Blot 492
Hybridization Assay. J Clin Microbiol 45:3411-3415. 493
494
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
22
Figure Legends 495
Figure 1: Top two panels show normalized fluorescence signals of the beads coated with 496
serotype 14 PS (Panel A) or serotype 9V PS (Panel B) obtained with the panel of test samples 497
(X axis). The bottom two panels show signal to noise ratio of the beads coated with probes for 498
serotype 21 (Panel C) and serotype 33F (Panel D) obtained with the panel of test samples. The 499
panel includes all 93 pneumococcal serotypes that have been so far identified and 4 isolates of 500
NT pneumococci representing both Group I and Group II. Dashed lines indicate cut off lines 501
and separate the positively reacting serotypes from the non-reacting serotypes. The top two 502
panels were obtained with the multiplexed inhibition type immunoassay using mAbs. The 503
bottom two panels were obtained with PCR-based multiplexed assay. 504
505
Figure 2: Normalized fluorescence signals of the PS-coated latex particles in the presence of 506
varying concentrations of homologous free inhibitory PS in solution. The serotype of inhibitory 507
PS are serotypes 1 (solid circle), 2 (solid triangle), 3 (solid square), 4 (solid diamond), 5 (open 508
circle), 6A (open triangle), 6B (open square), and 7F (open diamond). Two horizontal dotted 509
lines indicate 33% and 67% of normalized signals that were used as cut offs. 510
511
Figure 3: Normalized signals for the secondary serotypes in three samples. Abundance of the 512
secondary serotypes is 10 % (black bar), 1% (open bar), and 0% (grey bar). Two dotted 513
horizontal lines at 33% and 67% are used for decision making. 514
515
516
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
23
Table 1: specificity and sensitivity of mAb-based serotyping assay 517 518 No. Antibody Specificity IC50 (ng/ml)* No. Antibody Specificity** IC50 (ng/ml) 1 Hyp1G4 1 8 14 Hyp11AM2 11A/11D/11F 13 2 Hyp2M2 2 10 15 Hyp11AM1 11E/(11A/11D/11F) 15 3 Hyp3M6 3 6 16 Hyp12FM3 12F 26 4 Hyp4M3 4 6 17 Hyp14M11 14 5 5 Hyp5M3 5 12 18 Hyp15BG5 15B/(15C) 68 6 Hyp6AM3 6A 3 19 Hyp17FM6 17F/17A 6 7 Hyp6BM1 6B 77 20 Hyp18CM1 18C 5 8 Hyp6DM5 6C/6D 14 21 Hyp19AG1 19A 5 9 Hyp7FM15 7F/7A 52 22 Hyp19FM3 19F 5 10 Hyp8M2 8 10 23 Hyp20G5 20 29 11 Hyp9NM3 9N 8 24 Hyp22FM2 22F/22A 4 12 Hyp9VM7 9V/9A 1 25 Hyp23FG3 23F 16 13 Hyp10AG3 10A/39 58 26 Hyp33FG1 33F/33A 18
519 * IC50 indicates the PS concentration required to inhibit 50% of mAb binding to the ELISA 520
plate. 521
** Serotypes in parenthesis indicate serotypes with partial cross-reaction. Hyp10AG3 does not 522
cross-react with 10B unlike Danish factor serum 10d (12). 523
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
24
524
Table 2: Sequence of primers and probes for Reaction B
Specificity Oligo Code
Sequence (5′-3′) Source Specificity Oligo Code
Sequence (5′-3′) Source
LytA
5322 CAA CCG TAC AGA ATG AAG CGG
(33)
23B
5319 GGA TCG TTG TTC ATA GCG G
(33) 1006 GTC TTT CCG CCA GTG ATA AT 1003 ATA ATT ACT GGT CTG TGA TTT TTC TTT
3322 TTA TTC GTG CAA TAC TCG TGC G 3319 GAT AAT AAA GAA ATT ACT AAC CAT GTC GT
cpsA (except 25A, 25F, 38)
5202 GCA GTA CAG CAG TTT GTT GGA CTG ACC (20)
25F, 25A, 38
5343 GAC TAC AAA CTG CGG TAG TAG AAA TG
(33) 1039 GG TGC TGT CAC ACT CGT CAG This study 1008 ATA GGA ACT CTA GGG TTT AGT TTT TTC
3202 GAA TAT TTT CAT TAT CAG TCC CAG TC (20) 3343 TGG AAC AAT TCT AAT CGT TAA TAC G
7B, 7C, 40
5317 AAA ACT CAA GTA TCT GTG C(T)CA CCT T
(33)
5373 TGA GCT ATT TAA GGA CCT GGG
1001 TCC AAA TTT SAG TAA ACC AAC CTA A 10A, 10B 1024 GTT TAG AAA CCT TGC CCA GG (14)
3317 CAT CTC TAT TCG ACC TTG CGT TA 3373 GCA AGC GTC ACT TTC TTG A
21
5352 CAA TTC TAC TGA GTC CAT ATT ATG AAA
(33) 43
5369 AGA TCA AAT GGT GGT ATT AGG AA
(33) 1017 GAT AGT TTC TCT GTA TCA AAT AGC GA 1034 TCG GGT GTA CAA ATC CTA AAC TA
3352 ACC ATC GTA CCT GCA CCA TAA 3369 GGA ATA GAT CAT TAA CCC TAA TGA AT
33F, 33A, 37
5351 TCA ACT AGT CAA GGA TTT GAT GG
(14) 36
5368 CAA TTT CCC CTT ATT CTG TAG TTC
(33) 1016 TGA TAC CAC AAG TAA CAG AGT CG 1033 AGA TAA ATA CAT CAT TAT TGA CGA ACA
3351 CGT ATC AGA TTT GCG ATT TC 3368 TGG AGA TCC CCA AGA GAA AAT A
15B, 15C
5346 TAA TAA GCG GAT GAT TGT AGC G
(14) 48
5372 GCA TTT GGA GTT ATT GCC CTA C
(33) 1011 GAG CAG GAA TCA GAA CAC AAT C 1037 CCT ATA AAC ACA CTC AAA ACT AGC A
3346 TAT ACT GAT TAA CTT TCC AGA TGG G 3372 CGA CGG AAT CAA TAT AAA TAA GTG ATA
16A
5361 CCG CTC ACG GTA TGG ACT A
(33) 34
5608 TTA AAA GTA TTA TTG GTA GTG ATT CTT TTG
This study
1026 GGA GTA AAT GAT GTG TAG TGA AAA CC 1040 AA TCC ATT GGT ACT CTT CAC AAA
3361 CCA GCA ATA TAC TCA GGA AAT AAT TC 3608 TGT AAA GAC ATT CCC TGT AGG C
16F
5342 TTG TTC TTA CAT TTA GCC GTA GTG
(33) 35A, 35C,
42
5367 GGA GAC TA(/G)T TAA AAC TTT TTT CGT TC
(33) 1007 GTT GAA AGA ATA CGA TTC CTA CAA G 1032 CCT ACT TTA TTA ATG CCT GTT TGA G
3342 TCG TCG TTG AAA ACA ATT TCT TAC 3367 TTA AGT AAG TCT TCG CAA TCC AG
18
5607 AAT TGT TCT TTT CCT GTA CTC AGT C
(14) 35F, 47F
5521 ATA AAA AGA AAG TCT TTG CCA GAG
(33) 1039 GGA GGA CTT AGT CAA TTT ATC TTG 1005 AAA GTC ACA TC(T)T AAA ATT GAC ACA AC
3607 CGA ACC ATT GAA ACT ATC ATC TG 3321 CAA CTT TTG GAA GAT ACT GAA CAT AA
23A
5518 TTT ACT TTA ATT TAT AGC TTT TTG GCT AA
(33) 35B
5345 CTA ATT TGG CTA TGA AGC TAA TCC C
(33) 1002 TGC CTT TTT TAA CGA GGT TG 1010 AAG CGT GAA AAA TTT TAA TAA AAG AC
3318 GGT GCA TGA GTT AGG AGA AAG TG 3345 TAA CTT AAA TAG GCA TTA ACA AAA TAG GT
6C, 6D
5325 CATTTTAGTGAAGTTGGCGGTGGAGTT
This study
1042 TTTGCAGGTGTAGTAGGCAGG
3645 ACTTTACACGACAAACCCATAGAAGC
Oligonucleotide codes with 1000’s, 3000’s, or 5000’s respectively indicate names of probes, 525
reverse primers or forward primers. One of each primer pair shown in bold letters has a biotin 526
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
25
label at the 5’ end for detection with avidin. All the probes have an amine group at the 5’ end. 527
Stock primer solutions have 100 µM of oligonucleotides in water. 528
529
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
26
530
Table 3: Sequence of primers and probes for Reaction C
Specificity Oligo Code
Sequence (5′-3′) Source Specificity Oligo Code
Sequence (5′-3′) Source
cpsA for 25A, 25F, 38
5694 GGGAACGACTATCCTGTTGGAAATC
This study 15F, 15A
5347 TAT TTC CTT CCT ATG GGA CAA C
(33) 1046 GTCAGCACTTGGTTTCGTTCGAG 1012 AGT CCT TTC CCA AAT ATA GCA CT
3694 CTTCTGTTGATTCCGTCCTCGATC 3347 GCA AGC ATT TTA CCA AGT TCA TAA A
9N, 9L
5358 TCA ATG GCG ACT TTA TTT GC
(14) 33B, 33D
5366 TCG TTG GAT GAC AAA ACT CTT AC
(33) 1023 GAA CTT TGG GAA TAT AAT CAA AAG 1031 GCT CAA TGT GAC AGG GAG AA
3358 AGT CTA TTA TCT CCT GTA GGG TGC 3366 CCT CCC TGA GCC AAA ATA AC
28F, 28A
5354 CAG AGT TTG GTC GAG GTT CCT A
(33) 31
5344 TGA AAA TCC CTT AGT GAC ATC TG
1019 AGA ACT AAA TAC AGT GCA ATA ATT GG 1009 GAG CCT TCT CAA TAG TCA TAA AAA A (33)
3354 GCT CAA CTT TAT TTC TCT AGA ATA AAC A 3344 GCC ATA ATC AAA AAT AAG TTA GAC ATA A
10F, 10C
5355 TAG TTT TGG TTA CGT AGT TGT TGA CT
(33) 41F, 41A
5357 TGA CAC TAT TTA TAA TTG CTT TAT CCT T
(33) 1020 GAA AAC TTG CCC AAA TCC TT 1022 GGG TGC AAG GTG ATT ATG TAT
3355 GCA ATA(/G) AAT ACT GTA GCA TAC GAT AGT T 3357 TAG CGA GAA ACT ATC TGC ATC TTG
11B, 11C
5356 TCT GGT GCT AAG GGG ATC AA
(33) 29
5353 CCG AAA ATT GTT CAC AGG ATA C
(33) 1021 TGC ATA AGC TGA TTA TGA GCA TAG 1018 TAA CAA GCA GAA TAA GCA AAA TAG C
3356 CCA ATT ACT CCA TTA TCT ATT GCT AAT 3353 AGC TTT CTT TTG TAC GAC TCT TTT A
13
5348 GAT GGG AAA ATA CGA TAT GCT C
(33) 45
5370 TAT GCA GGA AAT ATC CGA GAA GG
(33) 1013 TGA GCT AAA TGT TGA ATA TTT ATA CCC 1035 CAG CAT ATC TTG CAC GAT AAT GAA
3348 GAA AAT CGT AAC ATG GAA AAA GTA A 3370 CCG TGA AAC AGA AAC GCT ATG
24F, 24A, 24B
5363 TCA ACA CTT ATG ATG G(A)TG CCT G
(33) 47A
5371 TAT TTG CCA TAA CGG ACT CTA GAA C
(33) 1028 CAC AAT CCA AAA CTT AAG TTG TTT C 1036 TTT TTA ACA ACC TTG TAT AGA ATA CCT C
3363 GCA GAA ACA AAA(/G) GTA AGA ATT ATA GAT ATC
3371 GCT AAA ATA ATA AAT AGC GAA CTT ACT ACA
12, 44, 46
5374 TGA ATA TGG ACG GTG GAG
(14) 33C
5375 CGA ATC GTC ATA AGG CAA AA
(33) 1025 GAA GAA GTT CAA CAA TCG CT 1038 ACC TAC TGT GAC AGG GAA TAG TAA A
3374 AGC AAA GAA AGC CGA AAG 3375 AAT AGG AGT AAC AAA GAG AAG CCT AA
19B, 19C
5362 AGA ATT CGG AGA TTT GTG GTA T
(33) NCC2
5433 AACACTTGGAACGGAGAATG
This study1027 TTC GTA CTG AAA ATT CAT TTC G 1044 GACCAGATTACCAAGATCCAGCAAC
3362 CAA TCC ACC TCC ATA AAC GA 3433 GCCCTTTGTTATACCTAGATGTTTC
27
5364 GCA GCC ACC TCT TCT CAT TC
(33) NCC2 & 3
5666 ATGCCAAATGGTTCACGGCTG
This study1029 CGC CAA ATT CTA TAC CAA CTA GTA T 1045 GTGACAGGTATCAAGTACGCAGTG
3364 GGA AGG AAC AAC CCA ACA AT 3666 CTGGTCGTCGATTGCTTTCACAC
32F, 32A
5365 GGT ATG CTT ACA ATG AGA CGC
(33) NCC1
5658 GCAAATCAGCCAGTAACTGTGA
This study1030 CCA CTT CCC AGA GGA AAA TA 1043 CTGTAGAACAGGCAAAGAGCAAGG
3365 AAT TCG TTC CCG GAT AAG ATG 3658 CAAGATAAGCTTTCTGCACCTCT
Oligonucleotide codes with 1000’s, 3000’s, or 5000’s respectively indicate names of probes, 531
reverse primers or forward primers. One of each primer pair shown in bold letters has a biotin 532
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
27
label at the 5’ end for detection with avidin. All the probes have an amine group at the 5’ end. 533
Stock primer solutions have 100 µM of oligonucleotides in water. 534
535
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from
28
Table 4: Testing clinical samples with PCR-based Multibead assay 536 537
Quellung Assay PCR-based Assay
Serotype Number Serotype Observed
13 3 13 3
29 1 29 1
31 3 31 3
34 4 34 4
15A 3 15A/15F 3
15C 8 15B/15C 8
16F 3 16F 3
18A 2 18A/18B/18C/18F 2
23A 3 23A 3
23B 2 23B 2
38 3 25F/25A/38 3
28A/28F 3 28A/28F 3
33A 2 33F/33A/37 2
35A/35C 2 35A/35C/42 2
35B 4 35B 4
35F 1 35F/47F 1
7C 3 7B/7C/40 3
NT* 3 NT (cpsA+) 3 538
* NT means non-typeable pneumococcal isolates. 539
540
541
on Septem
ber 22, 2020 by guesthttp://cvi.asm
.org/D
ownloaded from